Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Any role for probiotics in the therapy or prevention of autoimmune diseases? Up-to-date review.
Predictors of effectiveness of multidisciplinary rehabilitation treatment on motor dysfunction in multiple sclerosis.
Wnt Signaling in Remyelination in Multiple Sclerosis: Friend or Foe?
The case for measuring anti-drug antibodies in people with multiple sclerosis.
Author response.
Neuromyelitis optica spectrum disorders may be misdiagnosed as Wernicke's encephalopathy.
Drosophila Neuronal Injury Follows a Temporal Sequence of Cellular Events Leading to Degeneration at the Neuromuscular Junction.
Epitope mapping of anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in a mouse model of multiple sclerosis: microwave-assisted synthesis of the peptide antigens and ELISA screening.
Modifiable environmental factors in multiple sclerosis.
Co-existence of tumefactive MS and hepatitis C: A need for further screening and new therapeutic challenge.
[Progressive multifocal leukoencephalopathy associated to natalizumab: the importance of magnetic resonance imaging in its early diagnosis].
[Cormorbidity in multiple sclerosis and its therapeutic approach].
Glatiramer acetate-induced hepatitis in a patient with multiple sclerosis.
The secretome of mesenchymal stem cells: Potential implications for neuroregeneration.
An Unusual Case of Bilateral Multifocal Retinal Pigment Epithelial Detachment with Methanol-Induced Optic Neuritis.
Acute disseminated encephalomyelitis onset: evaluation based on vaccine adverse events reporting systems.
IL2RA Allele Increases Risk of Neuromyelitis Optica in Southern Han Chinese.
The effect of glia-glia interactions on oligodendrocyte precursor cell biology during development and in demyelinating diseases.
Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity.
Short-Term Effect of High-Dose Vitamin D on the Level of Interleukin 10 in Patients with Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Treatment with tanshinone IIA suppresses disruption of the blood-brain barrier and reduces expression of adhesion molecules and chemokines in experimental autoimmune encephalomyelitis.
Clinical neurophysiology of multiple sclerosis.
18F-DOPA, a Clinically Available PET Tracer to Study Brain Inflammation?
Association between Smoking and Health Outcomes in Postmenopausal Women Living with Multiple Sclerosis.
White Matter MS-Lesion Segmentation Using a Geometric Brain Model.

Pages